本帖最后由 老马 于 2013-3-13 13:43 编辑
2 L+ j# Z6 @2 s: T; V1 r1 \8 @& w( V5 p$ s
健择（吉西他滨）+顺铂+阿瓦斯汀* N E1 u2 k8 c& G$ u, Z
Gemzar +Cisplatin + Avastin; Q- x" v1 |9 X: f0 e) q
http://annonc.oxfordjournals.org/content/21/9/1804.full
2 }: @& d0 L, {# p d. W; @1 fOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) " o( B8 W* a& @! e- S4 g! J+ S
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 8 s) z5 |: v% x2 }" ~. G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. : \( {7 Z/ W. J+ C1 z- V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 787)
# l( ]2 u T' J9 `; W& p
华为网盘附件：
$ H( J" Q1 T! f+ R/ e5 U9 r【华为网盘】ava.JPG
' J" P. ]9 q. L! M& t3 H |
显身卡
